Cencora Raises Operating Income Guidance After Strong First Quarter and OneOncology Acquisition

First Quarter Performance Strengthens Company Outlook

Cencora (NYSE: COR) started fiscal 2026 on a high note, posting revenue of $85.9 billion for the first quarter—a 5.5% rise over last year. The company not only grew the top line but also delivered meaningful year-over-year improvement in adjusted diluted earnings per share (EPS), up 9.4% to $4.08. This robust quarter was fuelled by a mix of organic growth within its core U.S. and International Healthcare Solutions segments and the strategic acquisition of OneOncology, which fortifies Cencora’s position in specialty medical services organizations (MSOs).

Segment Results: U.S. Healthcare Leads, International Mixed

The U.S. Healthcare Solutions segment led the charge, reporting 5.0% revenue growth to $76.2 billion and a striking 21.0% increase in operating income. The gains were powered by higher specialty product sales and benefits from recent acquisitions, including Retina Consultants of America. Meanwhile, International Healthcare Solutions saw a robust 9.6% revenue increase to $7.6 billion, though operating income declined 13.9% due to margin pressures, particularly in the European distribution business.

Profit Margins and Cash Flow Show Resilience—Despite Elevated Operating Expenses

Gross profit climbed to $3.1 billion (GAAP), a notable 20.1% jump, with gross margin rising to 3.58%, partly attributed to improved specialty product margins. Adjusted operating income rose 11.9% to $1.06 billion, and adjusted operating margin ticked up to 1.24% from 1.16%, signaling incrementally better operational efficiency.

However, the quarter also saw operating expenses rise sharply by 24.8% to $2.3 billion due to acquired businesses and asset impairments. Importantly, net interest expense increased to $72.4 million, reflecting higher borrowing to support acquisitions. Despite these pressures, Cencora maintained strong net income and EPS growth, underpinned by effective integration of acquisitions and focused cost management.

Guidance Raised on Operating Income, EPS Reaffirmed—Strategic Acquisitions Bolstering Growth

Reflecting these results and its successful OneOncology acquisition, Cencora raised its fiscal 2026 adjusted operating income growth guidance to 11.5–13.5% (from the previous 8–10%). The company also reaffirmed its adjusted diluted EPS guidance, projecting a range of $17.45–$17.75 for the year—underscoring management’s confidence in continued earnings growth despite an environment of rising costs and integration expenses.

Strategic Expansion in Oncology and Specialty Services

The closing of the OneOncology deal cements Cencora’s MSO portfolio, boosting its specialty and oncology practice reach. Leadership called out the deepening of partnerships in cancer care, which is anticipated to drive long-term value and help offset challenges in other business segments.

Dividend, Capital Allocation, and Upcoming Events

Cencora’s board declared a quarterly cash dividend of $0.60 per share, payable March 2, 2026. Looking ahead, company management will present at both the Leerink Partners and Barclays Global Healthcare Conferences in March 2026—a potential opportunity for investors to gain further insight into strategy and expectations.

Key Takeaway for Investors

Cencora’s fiscal 2026 is off to a strong start, marked by disciplined growth, resilient margins, and confident forward guidance. Although investment spending and acquisition integration bring near-term expense pressure, the company’s enhanced specialty presence and reaffirmed earnings outlook position it as a leader in healthcare distribution and solutions for the year ahead.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI